PL2146714T3 - Zastosowanie 4-cyklopropylometoksy-n-(3,5-dichloro-1-tlenek-pirydyn-4-ylo)-5-(metoksy)pirydyno-2-karboksyamidu do leczenia zaburzeń ruchowych związanych z chorobą parkinsona - Google Patents

Zastosowanie 4-cyklopropylometoksy-n-(3,5-dichloro-1-tlenek-pirydyn-4-ylo)-5-(metoksy)pirydyno-2-karboksyamidu do leczenia zaburzeń ruchowych związanych z chorobą parkinsona

Info

Publication number
PL2146714T3
PL2146714T3 PL08787963T PL08787963T PL2146714T3 PL 2146714 T3 PL2146714 T3 PL 2146714T3 PL 08787963 T PL08787963 T PL 08787963T PL 08787963 T PL08787963 T PL 08787963T PL 2146714 T3 PL2146714 T3 PL 2146714T3
Authority
PL
Poland
Prior art keywords
oxidopyridin
cyclopropylmethoxy
carboxamide
parkinson
dichloro
Prior art date
Application number
PL08787963T
Other languages
English (en)
Polish (pl)
Inventor
Philippe Delay-Goyet
Claire Delgorge
Christine Menet
Gilles Poughon
Christine Ravinet-Trillou
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of PL2146714T3 publication Critical patent/PL2146714T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
PL08787963T 2007-04-19 2008-04-16 Zastosowanie 4-cyklopropylometoksy-n-(3,5-dichloro-1-tlenek-pirydyn-4-ylo)-5-(metoksy)pirydyno-2-karboksyamidu do leczenia zaburzeń ruchowych związanych z chorobą parkinsona PL2146714T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0702853A FR2915100B1 (fr) 2007-04-19 2007-04-19 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxalide pour le traitement des desordres moteurs lies a la maladie de parkinson
EP08787963A EP2146714B1 (fr) 2007-04-19 2008-04-16 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1 -oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des desordres moteurs lies a la maladie de parkinson
PCT/FR2008/000534 WO2008145841A1 (fr) 2007-04-19 2008-04-16 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1 -oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des desordres moteurs lies a la maladie de parkinson

Publications (1)

Publication Number Publication Date
PL2146714T3 true PL2146714T3 (pl) 2011-10-31

Family

ID=38712405

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08787963T PL2146714T3 (pl) 2007-04-19 2008-04-16 Zastosowanie 4-cyklopropylometoksy-n-(3,5-dichloro-1-tlenek-pirydyn-4-ylo)-5-(metoksy)pirydyno-2-karboksyamidu do leczenia zaburzeń ruchowych związanych z chorobą parkinsona

Country Status (33)

Country Link
US (1) US20100130554A1 (enExample)
EP (1) EP2146714B1 (enExample)
JP (1) JP5386478B2 (enExample)
KR (2) KR20150004885A (enExample)
CN (1) CN101663035B (enExample)
AR (1) AR066108A1 (enExample)
AT (1) ATE513548T1 (enExample)
AU (1) AU2008257322B2 (enExample)
BR (1) BRPI0810444A2 (enExample)
CA (1) CA2684174C (enExample)
CL (1) CL2008001136A1 (enExample)
CY (1) CY1111840T1 (enExample)
DK (1) DK2146714T3 (enExample)
EA (1) EA019194B1 (enExample)
ES (1) ES2367408T3 (enExample)
FR (1) FR2915100B1 (enExample)
HR (1) HRP20110666T1 (enExample)
IL (1) IL201448A (enExample)
JO (1) JO2678B1 (enExample)
MA (1) MA31367B1 (enExample)
ME (1) ME00935B (enExample)
MX (1) MX2009011284A (enExample)
MY (1) MY148092A (enExample)
NZ (1) NZ580482A (enExample)
PA (1) PA8776801A1 (enExample)
PL (1) PL2146714T3 (enExample)
PT (1) PT2146714E (enExample)
RS (1) RS51869B (enExample)
SI (1) SI2146714T1 (enExample)
TW (1) TWI439269B (enExample)
UY (1) UY31035A1 (enExample)
WO (1) WO2008145841A1 (enExample)
ZA (1) ZA200907251B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9533953B2 (en) * 2012-11-28 2017-01-03 Sanofi Method of preparation of crystal forms of 4-(cyclopropylmethoxy)-n-(3,5-dichloro-1-oxidopyridyn-4-yl)-5-methoxypyridine-2-carboxamide and crystal forms thereof
US9624100B2 (en) 2014-06-12 2017-04-18 Apple Inc. Micro pick up array pivot mount with integrated strain sensing elements
WO2025080415A1 (en) * 2023-10-12 2025-04-17 Alto Neuroscience, Inc. Treatment of neuropsychiatric disorders with tilivapram
WO2025079694A1 (ja) * 2023-10-12 2025-04-17 株式会社 メドレックス 経皮吸収組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4193926A (en) * 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
ES2176251T3 (es) * 1993-07-28 2002-12-01 Aventis Pharma Ltd Compuestos utilizados como inhibidores de pde iv y del factor de necrosis tumoral(tnf).
US6177077B1 (en) * 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
CA2395196C (en) * 1999-12-23 2006-02-21 Icos Corporation Cyclic amp-specific phosphodiesterase inhibitors
EP1370211A4 (en) * 2001-03-02 2005-02-09 Bristol Myers Squibb Co SIMULTANEOUS ADMINISTRATION OF MELANOCORTIN RECEPTOR AGONISTS AND A PHOSPHODIESTERASE HEMMER FOR THE TREATMENT OF DISEASES RELATED TO CYCLIC AMP
WO2004005258A1 (en) * 2002-07-02 2004-01-15 Merck Frosst Canada & Co. Di-aryl-substituted-ethane pyridone pde4 inhibitors
CA2518513C (en) * 2003-03-12 2014-05-20 Celgene Corporation N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses
WO2006135828A2 (en) * 2005-06-10 2006-12-21 Memory Pharmaceuticals Corporation Trisubstituted amines as phosphodiesterase 4 inhibitors
US20070021451A1 (en) * 2005-07-20 2007-01-25 Hamamatsu University School Of Medicine Method for preventing or treating neurologic damage after spinal cord injury

Also Published As

Publication number Publication date
KR20090130059A (ko) 2009-12-17
NZ580482A (en) 2011-10-28
KR101503942B1 (ko) 2015-03-18
AU2008257322B2 (en) 2013-06-13
JP2010524906A (ja) 2010-07-22
BRPI0810444A2 (pt) 2016-05-31
DK2146714T3 (da) 2011-10-10
MY148092A (en) 2013-02-28
CN101663035A (zh) 2010-03-03
EP2146714B1 (fr) 2011-06-22
AR066108A1 (es) 2009-07-22
FR2915100B1 (fr) 2009-06-05
EP2146714A1 (fr) 2010-01-27
SI2146714T1 (sl) 2011-10-28
TWI439269B (zh) 2014-06-01
JP5386478B2 (ja) 2014-01-15
IL201448A0 (en) 2010-05-31
WO2008145841A1 (fr) 2008-12-04
FR2915100A1 (fr) 2008-10-24
US20100130554A1 (en) 2010-05-27
RS51869B (sr) 2012-02-29
EA019194B1 (ru) 2014-01-30
UY31035A1 (es) 2008-11-28
HRP20110666T1 (hr) 2011-10-31
PA8776801A1 (es) 2008-11-19
AU2008257322A1 (en) 2008-12-04
ES2367408T3 (es) 2011-11-03
PT2146714E (pt) 2011-09-02
JO2678B1 (en) 2013-03-03
CN101663035B (zh) 2012-06-20
CA2684174A1 (fr) 2008-12-04
CY1111840T1 (el) 2015-10-07
MX2009011284A (es) 2009-11-02
CA2684174C (fr) 2014-02-25
ZA200907251B (en) 2011-04-28
TW200911247A (en) 2009-03-16
HK1141725A1 (en) 2010-11-19
ME00935B (me) 2012-06-20
CL2008001136A1 (es) 2009-01-16
MA31367B1 (fr) 2010-05-03
KR20150004885A (ko) 2015-01-13
EA200970970A1 (ru) 2010-02-26
ATE513548T1 (de) 2011-07-15
IL201448A (en) 2014-08-31

Similar Documents

Publication Publication Date Title
ZA200909191B (en) Catecholamine derivatives useful for the treatment of parkinson's disease
EP2166837A4 (en) DRUG COMBINATION USEFUL FOR THE TREATMENT OF SKIN DISORDERS
IL187168A0 (en) Improved nanobodiestm for the treatment of aggregation-mediated disorders
IL205153A0 (en) Compositions for treating parkinson's disease
IL195906A0 (en) Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
PT2229369T (pt) Derivados de 6,7-dialcoxi-quinazolina úteis para tratamento de distúrbios relacionados com o cancro
AU2008233088A8 (en) Calcimimetic compounds for use in the treatment of bowel disorders
IL206107A0 (en) Alpha-aminoamide derivatives useful in the treatment of psychiatric disorders
PL2146714T3 (pl) Zastosowanie 4-cyklopropylometoksy-n-(3,5-dichloro-1-tlenek-pirydyn-4-ylo)-5-(metoksy)pirydyno-2-karboksyamidu do leczenia zaburzeń ruchowych związanych z chorobą parkinsona
IL201451A0 (en) Use of 4 - cyclopropylmethoxy - n - (3, 5 - dichloro - 1 - oxidopyridin - 4 - yl) - 5 - (methoxy) pyridine - 2 - carboxamide for the treatment of spinal cord traumas
EP2214488A4 (en) COMPOSITIONS AND METHODS FOR TREATING PARKINSON'S DISEASE AND RELATED DISORDERS
GB0710277D0 (en) Use of antivirals in the treatment of medical disorders
BRPI0714307A2 (pt) Uso de benzamidas trifluormetil-substituídas no tratamento de distúrbios neurológicos
EP2099444A4 (en) USE OF D-SERIN DERIVATIVES FOR THE TREATMENT OF ANTIBODIES
IL201447A0 (en) Use of 4 - cyclopropylmethoxy - n - (3, 5 - dichloro - 1 - oxidopyridin - 4 - yl) - 5 - (methoxy) pyridine - 2 - carboxamide for the treatment of cranial traumas
SI2099780T1 (sl) 2-alkil-indazolne spojine za zdravljenje določenih motenj, povezanih s CŽS
IL194275A0 (en) Use of digitalis-like compounds in the treatment of affective disorders
HK1134650A (en) New combination for use in the treatment of inflammatory disorders